Provided herein are Vero cell lines that stably express Herpes Simplex Virus (HSV) ICP0 protein. These cells have the same morphology of Vero cells, exhibit stable expression of HSV ICP0 protein, and also efficiently complement replication of HSV ICP0 deficient virus for greater than 20, 30, or even 40 cell passages.

The present application relates to viral sensitizers. More specifically, the present application relates to neddylation-activating enzyme inhibitors, as well as processes for their preparation and methods of using such compounds and compositions as viral sensitizers. The present application includes a method of increasing permissiveness of a cell to a virus or genetic material encoding components of the virus, comprising administering an effective amount of a neddylation-activating enzyme (NAE) inhibitor, or a salt, solvate and/or prodrug thereof, to the cell.

The present disclosure provides materials and methods related to the purification of viral vectors. In particular, the present disclosure provides peptides, compositions, adsorbents, and related methods, capable of removing process-related impurities (e.g., host cell proteins, nucleic acids, and media components) and product-related impurities (e.g., product fragments, product aggregates, and inactive forms derived from product degradation by or association with other species in the cell culture harvest) from samples during the production and purification of lentivirus particles.

A method for producing reassortant influenza viruses is provided. Also provided are reassortant influenza viruses produced according to the method, as well as vaccines based on said reassortant influenza viruses.

The present invention relates to a mammalian non-human cell line, specifically Chinese hamster ovary (CHO) cells, that is genetically modified to express poxvirus host range genes CP77, K1L and/or SPI-1 which are not expressed in MVA, and to the use of said cell line in the reproduction of MVA.